Table 2 Perioperative outcome
Study | Abaza 2020 [13] | Kaouk 2020 [14] | Balasubramanian 2022 [16] | Zeinab 2022 [15] | Zeinab 2023 [10] | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Operative approach | Transperitoneal | Extraperitoneal | Transperitoneal | Extraperitoneal | Transperitoneal | Extraperitoneal | Transperitoneal | Extraperitoneal | Transperitoneal | Extraperitoneal |
Lymphadenectomy, N (%) | 0 | 0 | 24(52%) | 51(98%) | 37(94.9%) | 23(76.7%) | 35.0 (45.5%) | 76.0 (97.4%) | 101.0 (52.9%) | 192.0 (84.6%) |
Lymph nodes resected | 0 | 0 | 12 (3.7) | 5 (2.2) | 4.9(3.4) | 4.5(4.6) | 4.0 (8.2) | 5.0 (2.8) | 9.0 (8.3) | 6.0 (3.7) |
Nerve-sparing (unilateral or bilateral), N (%) | NA | 31(67.4%) | 45(86.5%) | NA | 56 (96.6%) | 47 (81.0%) | NA | |||
Operative time, minutes | 171.9 (26) | 198.1 (34.8) | 248.2(42.3) | 201(37.5) | 248(36) | 224(41) | 210.0 (37.1) | 190.0 (28.2) | 155.0(103.2) | 206.0(42.6) |
Estimated blood loss, mL | 112.5 (53.1) | 152.5 (82) | 117.6(93.7) | 145.7(87.7) | 130(70) | 138(87) | 100.0 (74.1) | 150.0 (74.1) | 75.0 (74.2) | 150.0 (74.2) |
Hospital stays (days or hours) | NA | 25.7 (14.4) | 4.3 (10.7) | 1.05(0.2) | 1.1(0.4) | 5.5 (13.3) | 4.6 (8.4) | 14.0 (8.1) | 7.5 (14.7) | |
Catheterization time, days | NA | NA | NA | 3.0 (0.7) | 7.0 (0.7) | 5.0 (0.9) | 7.0 (2.2) | |||
Pain | NA | Pain score at discharge 1 (2.9) | Pain score at discharge 2 (2.2) | Post-Operative Opioid Requirement (N = 23) | Post-Operative Opioid Requirement (N = 24) | Pain score at discharge 3.4 (1.9) | Pain score at discharge 3.7 (2.1) | Pain score at discharge 2.0 (0.7) | Pain score at discharge 2.0 (2.2) | |
PSM, N (%) | NA | 19(41.3%) | 14 (26.9%) | 10(25.6%) | 8(26.7%) | 12.0 (15.4%) | 20.0 (25.6%) | 61.0 (26.9%) | 55.0 (23.3%) | |
Continence, N (%) | NA | 24(60%) | 25(62.5%) | 30(76.9%) | 15(51.7%) | 56 (96.6%) | 47 (81.0%) | 133.0 (63.0%) | 87.0 (53.0%) | |
Postoperative complications, N (%) | NA | Â | Â | Â | Â | Â | Â | Â | Â | |
Overall | NA | 7(15.2%) | 6(11.5%) | 2(5.1%) | 3(10%) | 10.0 (12.8%) | 11.0 (14.1%) | 32.0 (13.4%) | 39.0 (16.4%) | |
Clavien-Dindo grade ≤ 2 | NA | 4(8.6%) | 2(3.8%) | NA | NA | 9(11.5%) | 6(7.7%) | 22.0 (68.7%) | 21.0 (53.8%) | |
Clavien-Dindo grade > 2 | NA | 3(6.5%) | 4(7.7%) | 2(5.1%) | 3(10%) | 2(2.5%) | 5(6.4%) | 10(31.2%) | 18.0 (46.1%) | |
Complications type, N (%) | ||||||||||
 Lymphocele | NA | 1.0(2.2%) | 3.0(5.8%) | 0.0 (0.0%) | 1.0(3.3%) | 1.0 (1.3%) | 6.0 (7.7%) | 7.0 (21.9%) | 14.0 (35.9%) | |
 Pelvic abscess | NA | 1.0(2.2%) | 1.0(1.9%) | NA | 1.0 (1.3%) | 0.0 (0.0%) | NA | |||
 Urinary tract infection | NA | 3.0(6.5%) | 1.0(1.9%) | NA | 0.0 (0.0%) | 1.0 (1.3%) | 8.0 (25.0%) | 2.0 (5.1%) | ||
 Others (ileus, bladder spasm, hematuria) | NA | 1.0(2.2%) | 2.0(3.8%) | NA | 8(10.2%) | 4.0(5.2%) | 7.0(21.9%) | 16.0(41%) | ||